In recent years, the OncoACP3 radiopharmaceutical (an ACP3-targeting radioligand) jointly developed by BMS and Philochem triggered major industry attention through a USD 1.35 billion licensing deal. Its diagnostic agent (⁶⁸Ga-OncoACP3) demonstrated extremely high tumor selectivity in Phase I clinical trials, while its therapeutic agent (²²⁵Ac-OncoACP3) delivers precise cancer cell killing via alpha particles, achieving both “high efficacy + low toxicity”.
In addition, ACP3 plays a key role in prostate cancer vaccines (such as Sipuleucel-T) and DNA vaccines (such as pTVG-HP). As competition around the PSMA target intensifies, ACP3, with stronger tumor specificity and lower background signal in normal tissues, has emerged as a differentiated “new blue ocean” target.
ACP3 (Acid Phosphatase 3), also known as Prostatic Acid Phosphatase (PAP), belongs to the acid phosphatase family and encodes an enzymatically active transmembrane protein involved in intracellular phosphorylation regulation, signal transduction, and mineral metabolism. It is one of the prostate cancer–specific biomarkers. Studies show that ACP3 is highly expressed in malignant prostate tissue but is nearly absent in normal tissues, making it an ideal tumor target. ACP3 participates in intracellular energy metabolism and signaling regulation by catalyzing the hydrolysis of phosphate monoesters into phosphate and alcohol.
Figure 1 Molecular mechanisms by which cellular PAP inhibits prostate cell proliferation and survival
Based on the biological functions of the ACP3 gene (signal transduction, regulation of apoptosis, mineral metabolism, etc.) and its central role in prostate cancer, Kyinno Biotechnology is developing a series of stable ACP3-overexpressing cell models to support multidimensional research:
1. Mechanistic studies: elucidating the “dual nature” of ACP3 in tumorigenesis
Signal pathway regulation: ACP3 influences key pathways such as PI3K-AKT and ERK through phosphorylation modifications. In prostate cancer, high ACP3 expression may promote tumor cell survival and invasiveness while suppressing immune surveillance. Kyinno Biotechnology’s cell lines can model its dynamic roles in tumor proliferation and invasion.
Drug resistance mechanism exploration: Combined with the latest studies (such as the CLIC3/PI3K-AKT pathway), these models explore the relationship between ACP3 and chemotherapy resistance, providing a target validation platform for combination therapies.
Figure 2 Interactions within the tumor microenvironment and therapeutic effects.
2. Drug screening: accelerating the development of radiopharmaceuticals and small-molecule inhibitors
Radiopharmaceutical target validation: Affinity testing of ligands such as OncoACP3 and evaluation of radionuclide (such as ²²⁵Ac) conjugation efficiency enable rapid screening of highly active candidate molecules.
Antitumor drug screening: Using ACP3-overexpressing models to screen inhibitors targeting ACP3-related signaling pathways, supporting the development of novel small-molecule drugs or combination treatment strategies.
3. Diagnostic development: optimizing ACP3 detection reagents and imaging technologies
ELISA kit optimization: Based on high ACP3 levels in overexpressing cells, assay sensitivity and specificity can be validated to support the development of next-generation diagnostic tools (such as high-precision ELISA).
4. Imaging probe development: By combining acid phosphatase staining solutions (lead nitrate method) with radiolabeling technologies, the potential of ACP3 for tumor localization applications is explored.
With the integration of radiopharmaceutical technologies (such as alpha-particle therapy), immunotherapy, and precision diagnostics, the application scope of ACP3 continues to expand. Kyinno Biotechnology will continue to deepen its focus in this field, collaborating with global research institutions and pharmaceutical companies to advance ACP3 from a “laboratory star” to a “clinical benchmark”, delivering more precise and effective treatment options for prostate cancer patients. To support ACP3-targeted drug development, Kyinno Biotechnology is building a series of ACP3-overexpressing cell models, with the list and validation data shown below. In addition, in vivo studies using ACP3-high-expressing VCAP cells are currently underway. We welcome you to contact us for more data.
ACP3 Cell Line List:
- VCAP-ACP3-KO
- PC3-ACP3
- HT-1080-ACP3
- 293T-ACP3
- CHOK1-ACP3
- MC38-ACP3
- CT26-ACP3
- 293T-mouse-ACP3
- CHOK1-mouse-ACP3
- 293T-rat-ACP3
- CHOK1-rat-ACP3
- 293T-cyno-ACP3
- CHOK1-cyno-ACP3
ACP3 Expression Validation Examples:
- 293T-ACP3
- CHOK1-ACP3
